Miiskin Launches Comprehensive Online Dermatology Platform, Expanding Access to Expert Skin Care
Patients now have direct access to fast, affordable, full-service skin treatment from board-certified dermatologists through a secure, HIPAA-compliant platform.
May 28, 2025 — Miiskin, a full-service, digital dermatology platform expanding access to expert skincare, today announces the launch of its nationwide virtual care solution that connects U.S. patients with independent, board-certified dermatologists. The platform meets rising patient demand for digital dermatological care and leverages technology to deliver accessible, affordable, and full-service care for patients, while helping providers streamline and scale their practices.
The new Miiskin platform connects patients with dermatologists in their state using photo- and video-based consultations. The patient-facing website, app, and dedicated provider portal allow dermatologists to diagnose and treat many skin conditions, including acne, hyperpigmentation, hair loss, and signs of aging. Providers using Miiskin have full prescription authority, including the ability to prescribe treatments like Accutane when medically appropriate.
“Scheduling an in-person appointment with a dermatologist can take weeks or even months, and on average, can cost over $200 per visit. This puts care out of reach for many, especially those with busy schedules,” said Jon Friis, founder and CEO of Miiskin. “Unlike many platforms, our doctors can guide patients through a full care plan and prescribe what’s legitimately needed, not just compounded options. We’re proud to offer timely, reliable, and affordable solutions to improve access to skin health for everyone.”
For providers, Miiskin offers a HIPAA-compliant platform that improves virtual care delivery while maintaining clinical autonomy, including how much they charge for their services. Patients pay providers directly through the Miiskin platform, and Miiskin charges a simple platform fee to the provider. The platform automates patient intake to enable efficient case management, drive revenue growth and expand the provider’s patient network. The provider portal features a patient dashboard, high-resolution image and intake form review, secure messaging, and integrated ePrescriptions.
“The Miiskin provider platform has been incredibly easy to use and has played a key role in expanding my patient network,” said Dr. Amit Om, MD, FAAD, dermatologist and owner of Om Dermatology.“It helps me connect virtually, build meaningful relationships, and deliver care when it’s needed most. Patients can message dermatologists like me directly, get timely answers, and receive support for skin concerns without the long wait for an in-person visit. Patients know exactly what they’ll get. Miiskin is helping create more accessible care and real professional growth.
Miiskin is certified by LegitScript, a leading certification and monitoring service for online healthcare. This recognition affirms that Miiskin and its providers meet key standards for safety, transparency, and regulatory compliance, ensuring they operate legally and ethically.
To learn more about the Miiskin app, visit www.miiskin.com.
About Miiskin
Miiskin is a leading digital dermatology platform that is expanding access to expert skin care for patients in the U.S., connecting them with independent, board-certified dermatologists. With fast access to online dermatology, Miiskin makes it easy to get treatment for acne, aging skin, hyperpigmentation, hair loss, and other more complicated skin concerns without long waits or in-person visits. Patients control their care, choose their pharmacy, and avoid rigid medication subscriptions. For providers, Miiskin provides a secure, HIPAA-compliant platform that streamlines patient management, allowing dermatologists to focus on delivering high-quality care. Miiskin’s mission is to bring accessible dermatological care to 100 million people by 2040. For more information, visit www.miiskin.com.
Media Contact
Jensen Charbonneau
miiskin@ampublicrelations.com
No comments yet. Be the first to comment!
0 Comments